Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

por Julg, Boris, Stephenson, Kathryn E., Wagh, Kshitij, Tan, Sabrina C., Zash, Rebecca, Walsh, Stephen, Ansel, Jessica, Kanjilal, Diane, Nkolola, Joseph, Walker-Sperling, Victoria E. K., Ophel, Jasper, Yanosick, Katherine, Borducchi, Erica N., Maxfield, Lori, Abbink, Peter, Peter, Lauren, Yates, Nicole L., Wesley, Martina S., Hassell, Tom, Gelderblom, Huub C., deCamp, Allen, Mayer, Bryan T., Sato, Alicia, Gerber, Monica W., Giorgi, Elena E., Gama, Lucio, Koup, Richard A., Mascola, John R., Monczor, Ana, Lupo, Sofia, Rolle, Charlotte-Paige, Arduino, Roberto, DeJesus, Edwin, Tomaras, Georgia D., Seaman, Michael S., Korber, Bette, Barouch, Dan H.
Publicado 2022